Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

2014 San Antonio Breast Cancer Symposium

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”

Hope S. Rugo, MD, on the Phase II FIRST Study

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.

Breast Cancer

Gunter von Minckwitz, MD

Gunter von Minckwitz, MD, on the Phase III ICE Trial

Gunter von Minckwitz, MD, of the University of Frankfurt, offers his thoughts on abstract S3-04, "The phase III ICE study: Adjuvant ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer."

Breast Cancer

Matthew J. Ellis, MD

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive Breast Cancer."

Breast Cancer

Clifford A. Hudis, MD, FACP

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Breast Cancer

Harold J Burstein MD PhD and Lisa A Carey MD

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

The TNT trial comparing docetaxel to carboplatin
The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
Pembrolizumab in a phase Ib study

Sep

Today In Oncology

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Related Videos

Hope S. Rugo, MD, on the Phase II FIRST Study

Gunter von Minckwitz, MD, on the Phase III ICE Trial

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test

New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer

CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing

Robert Kyle Myeloma Expert Dies at 98